Problems for Alcon's (US) non-silicone intra-ocular lens (IOL):
This article was originally published in Clinica
Shortly after Alcon (US) introduced its acrylic intra-ocular lens some months ago, rumours of problems with the new product began to circulate. In April, it became official: there were problems with "glistening", the company informed surgeons and ophthalmologists, and began a voluntary recall. Alcon believes the culprit is the US packaging; no problems have been found in products sold overseas. Meanwhile, both Alcon and the FDA are investigating.
You may also be interested in...
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.